Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 17Thoracic 2Tumor-Agnostic 1Genitourinary 1

Conditions

Lung Neoplasms 4Anemia 4Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Small Cell Lung Carcinoma 1Pleural Effusion, Malignant 1Pleural Effusion 1Neutropenia 1Multiple Myeloma 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Drug-Related Side Effects and Adverse Reactions 1Breast Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 61Carboplatin 44Pemetrexed 31Paclitaxel 31Docetaxel 31Cisplatin 27Gemcitabine 24Nivolumab 23Erlotinib Hydrochloride 21Bevacizumab 18Ipilimumab 11osimertinib 10Drug Therapy 10atezolizumab 9Radiosurgery 9Cyclophosphamide 9Cetuximab 9Blood Specimen Collection 9durvalumab 8cemiplimab 8Radiotherapy 8budigalimab 7Fluorouracil 7Dexamethasone 7trametinib 6fludarabine 6dostarlimab 6avelumab 6Taxes 6130-nm albumin-bound paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Darbepoetin alfa × Thoracic × Clear all
NCT00858364 2022-11-30

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Amgen

Phase 3 Terminated
2,549 enrolled 19 charts
Classical hematologyThoracic

Anemia, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Pleural Effusion, Pleural Effusion, Malignant

NCT00119613 2008-08-08

A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa

Amgen

Phase 3 Completed
600 enrolled
Thoracic

Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡